Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 20/20 | 0.70 |
| ▸ | VEGFA | P15692 | 4/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ARNT | P27540 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26812591 | 0.91 | EPAS1 (0.72) | EPAS1VEGFA | |
| SCHEMBL24317170 | 0.83 | EPAS1 (0.68) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL24317188 | 0.83 | EPAS1 (0.66) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL24317763 | 0.83 | EPAS1 (0.68) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL26813176 | 0.82 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL16560888 | 0.82 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL24317207 | 0.82 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL16560864 | 0.81 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL22240394 | 0.81 | EPAS1 (1.00) | EPAS1VEGFA | |
| Belzutifan SCHEMBL29388851 | 0.81 | EPAS1 (1.00) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081407-A1 | METHODS OF PREPARING SUBSTITUTED INDANES | PELOTON THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081407-A1 | METHODS OF PREPARING SUBSTITUTED INDANES | HIF1AN, EGLN2, HIF1A | EPAS1 25/4885VEGFA 1713/4885CYP2C9 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.